|
Investigation of a nanoparticle albumin-bound mTOR inhibitor, nab-rapamycin for
|
4R42CA171552-02
|
$924,745
|
$924,745
|
DESAI, NEIL
|
AADI, LLC
|
|
A novel phosphodiesterase isozyme target and class of inhibitors for lung cancer
|
1R43CA189613-01A1
|
$224,879
|
$224,879
|
CANZONERI, JOSHUA
|
ADT PHARMACEUTICALS, INC.
|
|
Pathophysiology of Chemotherapy-Induced Cognitive Deficits in Juvenile Rats
|
5R01CA182284-02
|
|
$0
|
COLE, PETER
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Pathophysiology of Chemotherapy-Induced Cognitive Deficits in Juvenile Rats
|
6R01CA182284-03
|
$346,525
|
$346,525
|
COLE, PETER
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
DNA Mismatch repair and cancer in murine models
|
5R01CA076329-18
|
$294,353
|
$97,136
|
EDELMANN, WINFRIED
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
DNA Mismatch repair and cancer in murine models
|
6R01CA076329-19
|
$86,232
|
$28,457
|
EDELMANN, WINFRIED
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Core Support for Cancer Center
|
3P30CA013330-43S1
|
$199,871
|
$25,983
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Core Support for Cancer Center
|
5P30CA013330-42
|
|
$0
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Proton-coupled folate/antifolate transport
|
5R01CA082621-17
|
|
$0
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Core Support for Cancer Center
|
6P30CA013330-43
|
$3,696,138
|
$480,498
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Proton-coupled folate/antifolate transport
|
6R01CA082621-18
|
$486,473
|
$486,473
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Osteosarcoma: Patient Derived Xenograft Preclinical Testing
|
1U01CA199221-01
|
|
$0
|
GORLICK, RICHARD
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Osteosarcoma: Patient Derived Xenograft Preclinical Testing
|
6U01CA199221-02
|
$260,103
|
$260,103
|
GORLICK, RICHARD
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Development of Novel Drugs to Alleviate CPT-11 Toxicity
|
5R01CA161879-04
|
$326,465
|
$326,465
|
MANI, SRIDHAR
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Development of Novel Drugs to Alleviate CPT-11 Toxicity
|
6R01CA161879-05
|
$1
|
$1
|
MANI, SRIDHAR
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Inhibition of Senescence to Increase Cancer Cell Death: A New Paradigm
|
2R01CA077263-15A1
|
|
$0
|
MCDAID, HAYLEY
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Inhibition of Senescence to Increase Cancer Cell Death: A New Paradigm
|
6R01CA077263-16
|
$429,836
|
$429,836
|
MCDAID, HAYLEY
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Inhaled DNA demethylating therapy for lung cancer and bronchial premalignancy
|
5R01CA154755-05
|
|
$0
|
PEREZ-SOLER, ROMAN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Inhaled DNA demethylating therapy for lung cancer and bronchial premalignancy
|
6R01CA154755-06
|
$53,995
|
$53,995
|
PEREZ-SOLER, ROMAN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Development of a heterologous bio-production system for the clinically important
|
1R43CA171485-01A1
|
$194,740
|
$194,740
|
KITTENDORF, JEFFREY
|
ALLUVIUM BIOSCIENCES, INC.
|
|
Therapeutic Vaccine Targeting CMV Antigens in Glioblastoma
|
2R42CA153845-02
|
$1,227,385
|
$1,227,385
|
SAMPSON, JOHN
|
ANNIAS IMMUNOTHERAPEUTICS, INC.
|
|
A FAP-Activated Proteasome Inhibitor for Killing Solid Tumors
|
5R42CA156930-03
|
$532,072
|
$532,072
|
JONES, BARRY
|
ARISAPH PHARMACEUTICALS, INC.
|
|
Cellular biofactories for therapeutic protein synthesis in tumor microenvironment
|
1R21CA193064-01
|
$1
|
$1
|
BHATNAGAR, PARIJAT
|
BAYLOR COLLEGE OF MEDICINE
|
|
ESTROGEN RECEPTOR TARGETED TREATMENT OF NON-MUSCLE INVASIVE BLADDER CANCER
|
5K23CA160664-03
|
$132,711
|
$132,711
|
GODOY, GUILHERME
|
BAYLOR COLLEGE OF MEDICINE
|
|
SPORE in Lymphoma
|
5P50CA126752-09
|
$2,184,999
|
$240,350
|
HESLOP, HELEN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Identifying Cell Stress Proteins that Predict Clinical Response in Pediatric AML
|
5R01CA164024-03
|
$376,095
|
$376,095
|
HORTON, TERZAH
|
BAYLOR COLLEGE OF MEDICINE
|
|
Characterization and targeting BRIT1 deficiency in breast cancer
|
5R01CA155151-05
|
$324,738
|
$107,164
|
LI, KAIYI
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
2P30CA125123-09
|
$3,155,163
|
$189,310
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-09S2
|
$112,151
|
$6,729
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-09S3
|
$183,048
|
$10,983
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Translational Research in Breast Cancer (SPORE)
|
5P50CA186784-02
|
$2,184,998
|
$262,200
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Using Stat3 Signaling Profiles to Understand Chemotherapy Resistance in AML
|
5R01CA175026-02
|
$399,401
|
$399,401
|
REDELL, MICHELE
|
BAYLOR COLLEGE OF MEDICINE
|
|
The Role of SRC-1 in Breast Cancer
|
5R01CA112403-09
|
$269,732
|
$89,012
|
XU, JIANMING
|
BAYLOR COLLEGE OF MEDICINE
|
|
A novel miR-198 replacement therapy for pancreatic cancer
|
1R01CA183984-01A1
|
$472,669
|
$236,335
|
YAO, QIZHI
|
BAYLOR COLLEGE OF MEDICINE
|
|
The Role of Growth Factor Receptor Trafficking in Tumorigenesis
|
3R01CA166749-03S1
|
$65,036
|
$21,462
|
ZAGE, PETER
|
BAYLOR COLLEGE OF MEDICINE
|
|
The Role of Growth Factor Receptor Trafficking in Tumorigenesis
|
5R01CA166749-03
|
$318,913
|
$105,241
|
ZAGE, PETER
|
BAYLOR COLLEGE OF MEDICINE
|
|
Complex Role of HSF1 in Breast Cancer
|
5R01CA176326-02
|
$374,219
|
$123,492
|
CALDERWOOD, STUART
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Hyperpolarized NMR for Studies of Cancer Therapies Targeting the Warburg Effect
|
5R01CA169470-03
|
$361,050
|
$180,525
|
GRANT, AARON
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
DF/HCC Kidney Cancer SPORE
|
2P50CA101942-11A1
|
$2,185,000
|
$262,200
|
MCDERMOTT, DAVID
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
BMX-001 as a Therapeutic Agent for Treatment of High-Grade Gliomas
|
1R44CA195749-01
|
$976,447
|
$976,447
|
CRAPO, JAMES
|
BIOMIMETIX JV, LLC
|
|
IGPR-1 in colon cancer chemotherapy
|
1R21CA193958-01
|
$213,629
|
$213,629
|
RAHIMI, NADER
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
Cancer and Leukemia Group B CCOP Research Base
|
3U10CA037447-29S2
|
$334,740
|
$153,980
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Epstein-Barr Virus LMP1-Mediated Oncogenecity
|
5R01CA085180-14
|
$701,405
|
$350,703
|
KIEFF, ELLIOTT
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Molecular Pathogenesis of the Hamartoma Syndromes
|
5P01CA120964-09
|
$1,781,486
|
$659,150
|
KWIATKOWSKI, DAVID
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Engineering a supramolecular platinum nanoparticle for pediatric cancer
|
5R21CA186009-02
|
$181,037
|
$181,037
|
SENGUPTA, SHILADITYA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Nanoparticle Co-delivery of RNAi and Chemotherapy for Multidrug Resistant Cancers
|
5R00CA160350-05
|
$248,814
|
$248,814
|
SHI, JINJUN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Theranostic nanoparticles for dual modality cancer therapy
|
1SC2CA206194-01A1
|
$157,000
|
$157,000
|
CZAJKOWSKA, ANETA
|
BROOKLYN COLLEGE
|
|
PET Kinetic Modeling of Inhibiting Glycolysis in Ovarian Cancer
|
1R21CA198795-01
|
$185,247
|
$185,247
|
AVRIL, NORBERT
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-25S1
|
$37,026
|
$4,443
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-25S2
|
$49,999
|
$6,000
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
Total relevant funding to Chemotherapy for this search: $267,914,843
|